Login to Your Account



Financings Roundup

Rib-X Skips IPO, Opts for $67.5M Equity Financing

By Catherine Shaffer
Staff Writer

Friday, November 30, 2012

Rib-X Pharmaceuticals Inc. walked back from its proposed initial public offering (IPO) filed almost exactly a year ago, arranging instead for a $67.5 million Series 2 preferred stock financing led by a new investor, Vatera Healthcare Partners.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription